

## Management Change of U.S. Subsidiary Santen Incorporated

**March 22, 2002** --- Santen Pharmaceutical Co., Ltd. today announced that the President of its U.S. subsidiary, Santen Incorporated, will be changed as of April 1, 2002 as following:

### 1. Names and Titles of Newly-assigned and Current Management

	Newly-assigned President	Current President
Name	Ichiro Otokozawa	Merwin Jerold Hansen
Title as of April 1, 2002	President Santen Incorporated (Concurrent)	(Resigned)
Current Title	Corporate Officer Head of Corporate Development and Administration Division Santen Pharmaceutical Co., Ltd. ( To be continued )	Director and Corporate Officer of Santen Pharmaceutical Co., Ltd.; and President of Santen Incorporated

Note: Merwin Jerold Hansen will resign as Director and Corporate Officer of Santen Pharmaceutical Co., Ltd., and President of Santen Incorporated as of March 31, 2002. He will remain a consultant to Santen for a certain period of time.

### 2. Date of Assignment

April 1, 2002

### 3. Outline of Santen Incorporated

Name: Santen Incorporated  
Location: Napa, California, USA  
Establishment: January 1993  
Equity Ownership: 100% subsidiary of Santen Pharmaceutical Co., Ltd.  
Paid-in Capital: US\$ 8,785 thousand  
Number of Employees: Approximately 200  
Business: Development, manufacture and sale of prescription pharmaceuticals  
Main Products: Quixin (anti-infective ophthalmic solution), Betimol (anti-glaucoma ophthalmic solution) and Alamast (anti-allergic ophthalmic solution)